Clinical Trial Update: Keratinocyte Growth Factor to Prevent Acute GVHD [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluated keratinocyte growth factor (palifermin) for prevention of acute graft-versus-host disease and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Palifermin (palifermin)

Snippet

Sponsor: FDA Office of Orphan Products Development | Conditions: Graft-vs-Host Disease | Phase 1, Phase 2 | Status: COMPLETED